IMV Inc. (IMV)
Stock Price:
$2.87 USD
-0.04 (-1.37%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
177.09M |
| Revenue (ttm) |
433,588 |
| Net Income (ttm) |
-20.89M |
| Shares Out |
61.17M |
| EPS (ttm) |
-0.34 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$2.87 |
| Previous Close |
$2.91 |
| Change ($) |
-0.04 |
| Change (%) |
-1.37% |
| Day's Open |
2.95 |
| Day's Range |
2.83 - 3.05 |
| Day's Volume |
201,991 |
| 52-Week Range |
1.35 - 5.12 |
More Stats
| Market Cap |
177.09M |
| Enterprise Value |
173.81M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
61.17M |
| Float |
54.82M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.34 |
| FCF / Share |
-0.43 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
444,126 |
| Short Ratio |
0.94 |
| Short % of Float |
n/a |
| Beta |
2.04 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
408.43 |
| PB Ratio |
21.87 |
| Revenue |
433,588 |
| Operating Income |
-19.94M |
| Net Income |
-20.89M |
| Free Cash Flow |
-21.19M |
| Net Cash |
3.28M |
| Net Cash / Share |
0.05 |
| Gross Margin |
100.00% |
| Operating Margin |
-4,599.65% |
| Profit Margin |
-4,817.80% |
| FCF Margin |
-4,888.03% |
| ROA |
-65.65% |
| ROE |
-265.73% |
| ROIC |
-242.90% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
6 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$5.26*
(83.28% upside)
Low
3.00
Current: 2.87
High
9.41
Target: 5.26
*Average 12-month USD price target from 8 stock analysts.
Financial Performance
Financial numbers in millions CAD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 0.57 | 0.48 | 0.22 | 0.13 |
| Revenue Growth | 17.6% | 117.57% | 71.16% | - |
| Gross Profit | 0.57 | 0.48 | 0.22 | 0.13 |
| Operating Income | -26.13 | -20.55 | -11.06 | -8.37 |
| Net Income | -27.37 | -21.94 | -12.03 | -8.77 |
| Shares Outstanding | 49.65 | 43.77 | 38.66 | 91.87 |
| Earnings Per Share | -0.55 | -0.50 | -0.31 | -0.10 |
| Operating Cash Flow | -27.29 | -17.22 | -9.00 | -7.07 |
| Capital Expenditures | -0.48 | -2.17 | -0.39 | -0.12 |
| Free Cash Flow | -27.76 | -19.39 | -9.38 | -7.19 |
| Cash & Equivalents | 14.07 | 14.90 | 14.91 | 3.84 |
| Total Debt | 9.77 | 9.55 | 6.54 | 3.78 |
| Net Cash / Debt | 4.30 | 5.35 | 8.37 | 0.07 |
| Assets | 22.43 | 22.93 | 17.03 | 5.95 |
| Liabilities | 15.99 | 18.61 | 10.69 | 5.88 |
| Book Value | 6.45 | 4.32 | 6.34 | 0.07 |
Numbers in millions CAD, except per-share numbers.
Company Details
| Full Name |
IMV Inc. |
| Country |
Canada |
| Employees |
62 |
| CEO |
Frederic Ors |
Stock Information
| Ticker Symbol |
IMV |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: IMV |
Description
IMV Inc., a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DPX drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. The company develops DPX-Survivac, T cell activating immunotherapy that is in Phase II clinical trials for ovarian cancer and diffuse large B-cell lymphoma. It also develops DPX-RSV, a B cell epitope peptide vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7; and vaccine candidates for malaria and the Zika virus. IMV Inc. has collaboration and license agreements with Merck & Co., Inc., Dana-Farber Cancer Institute, Incyte Corporation, and Leidos Inc, as well as with Zoetis and The Wistar Institute; and a preclinical therapeutic research collaboration with Navidea Biopharmaceuticals, Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.